ibudilast has been researched along with Allodynia in 6 studies
| Excerpt | Relevance | Reference |
|---|---|---|
| " In this study, we investigated the effect of ibudilast, a phosphodiesterase inhibitor, on oxaliplatin-induced mechanical allodynia and histological changes in rats." | 8.02 | Ibudilast suppresses oxaliplatin-induced mechanical allodynia and neurodegeneration in rats. ( Egashira, N; Goto, Y; Iba, H; Iwasaki, K; Katsurabayashi, S; Kawashiri, T; Kubota, K; Takahashi, R; Taniguchi, C; Watanabe, T; Yamamoto, S, 2021) |
| " Four experiments examined whether Ibudilast, a clinically approved neuroimmune therapy, would reduce tactile allodynia and memory impairments caused by oxaliplatin in laboratory rats." | 7.85 | Ibudilast reduces oxaliplatin-induced tactile allodynia and cognitive impairments in rats. ( Cao, J; Fardell, JE; Forrest, DRL; Hutchinson, MR; Johnston, IN; Matsos, A; Si, E; Tan, M, 2017) |
| " The markedly delayed efficacy of all 3 glial modulatory drugs may prove instructive for interpretation of apparent drug failures after shorter dosing regimens." | 5.40 | Systemic administration of propentofylline, ibudilast, and (+)-naltrexone each reverses mechanical allodynia in a novel rat model of central neuropathic pain. ( Ellis, A; Falci, S; Favret, J; Johnson, KW; Maier, SF; Rice, KC; Watkins, LR; Wieseler, J, 2014) |
| " In this study, we investigated the effect of ibudilast, a phosphodiesterase inhibitor, on oxaliplatin-induced mechanical allodynia and histological changes in rats." | 4.02 | Ibudilast suppresses oxaliplatin-induced mechanical allodynia and neurodegeneration in rats. ( Egashira, N; Goto, Y; Iba, H; Iwasaki, K; Katsurabayashi, S; Kawashiri, T; Kubota, K; Takahashi, R; Taniguchi, C; Watanabe, T; Yamamoto, S, 2021) |
| " Four experiments examined whether Ibudilast, a clinically approved neuroimmune therapy, would reduce tactile allodynia and memory impairments caused by oxaliplatin in laboratory rats." | 3.85 | Ibudilast reduces oxaliplatin-induced tactile allodynia and cognitive impairments in rats. ( Cao, J; Fardell, JE; Forrest, DRL; Hutchinson, MR; Johnston, IN; Matsos, A; Si, E; Tan, M, 2017) |
| "Ibudilast was generally well-tolerated with mild, transient nausea reported as the most common adverse event (66." | 2.80 | Glial Attenuation With Ibudilast in the Treatment of Medication Overuse Headache: A Double-Blind, Randomized, Placebo-Controlled Pilot Trial of Efficacy and Safety. ( Hutchinson, MR; Johnson, JL; Johnson, K; Kwok, YH; Rolan, PE; Sumracki, NM; Swift, JE; Tuke, J; Williams, DB, 2015) |
| "Ibudilast is a phosphodiesterase inhibitor with anti-inflammatory activity, but its effect on activated microglia in chronic neuropathic pain is poorly understood." | 1.48 | Ibudilast produces anti-allodynic effects at the persistent phase of peripheral or central neuropathic pain in rats: Different inhibitory mechanism on spinal microglia from minocycline and propentofylline. ( Asaki, T; Fujita, M; Hasegawa, M; Omachi, S; Rokushima, M; Sakaguchi, G; Shinohara, S; Tamano, R; Yogo, E; Yoneda, S, 2018) |
| "Facial allodynia is a migraine symptom that is generally considered to represent a pivotal point in migraine progression." | 1.46 | Supradural inflammatory soup in awake and freely moving rats induces facial allodynia that is blocked by putative immune modulators. ( Bastos, LF; Brown, K; Cady, S; Ellis, A; Johnson, K; Maier, SF; McFadden, A; Rezvani, N; Rice, KC; Sprunger, D; Stone, K; Watkins, LR; Wieseler, J, 2017) |
| " The markedly delayed efficacy of all 3 glial modulatory drugs may prove instructive for interpretation of apparent drug failures after shorter dosing regimens." | 1.40 | Systemic administration of propentofylline, ibudilast, and (+)-naltrexone each reverses mechanical allodynia in a novel rat model of central neuropathic pain. ( Ellis, A; Falci, S; Favret, J; Johnson, KW; Maier, SF; Rice, KC; Watkins, LR; Wieseler, J, 2014) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 5 (83.33) | 24.3611 |
| 2020's | 1 (16.67) | 2.80 |
| Authors | Studies |
|---|---|
| Egashira, N | 1 |
| Goto, Y | 1 |
| Takahashi, R | 1 |
| Iba, H | 1 |
| Yamamoto, S | 1 |
| Watanabe, T | 1 |
| Kubota, K | 1 |
| Kawashiri, T | 1 |
| Taniguchi, C | 1 |
| Katsurabayashi, S | 1 |
| Iwasaki, K | 1 |
| Wieseler, J | 2 |
| Ellis, A | 2 |
| McFadden, A | 1 |
| Stone, K | 1 |
| Brown, K | 1 |
| Cady, S | 1 |
| Bastos, LF | 1 |
| Sprunger, D | 1 |
| Rezvani, N | 1 |
| Johnson, K | 2 |
| Rice, KC | 2 |
| Maier, SF | 2 |
| Watkins, LR | 2 |
| Johnston, IN | 1 |
| Tan, M | 1 |
| Cao, J | 1 |
| Matsos, A | 1 |
| Forrest, DRL | 1 |
| Si, E | 1 |
| Fardell, JE | 1 |
| Hutchinson, MR | 2 |
| Fujita, M | 1 |
| Tamano, R | 1 |
| Yoneda, S | 1 |
| Omachi, S | 1 |
| Yogo, E | 1 |
| Rokushima, M | 1 |
| Shinohara, S | 1 |
| Sakaguchi, G | 1 |
| Hasegawa, M | 1 |
| Asaki, T | 1 |
| Favret, J | 1 |
| Johnson, KW | 1 |
| Falci, S | 1 |
| Johnson, JL | 1 |
| Kwok, YH | 1 |
| Sumracki, NM | 1 |
| Swift, JE | 1 |
| Williams, DB | 1 |
| Tuke, J | 1 |
| Rolan, PE | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Phase 2, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Full-Factorial, Parallel-Group Study Evaluating Safety and Efficacy of Naltrexone-Acetaminophen Combination in Acute Migraine Treatment in Adults, With Exploratory Focus on Co-Occurring[NCT05685225] | Phase 2 | 300 participants (Anticipated) | Interventional | 2024-03-01 | Not yet recruiting | ||
| A Clinical Trial to Assess a Single Dose of Low-Dose Naltrexone and Acetaminophen Combination and Its Components in the Acute Treatment of Migraine[NCT03061734] | Phase 2 | 92 participants (Actual) | Interventional | 2017-02-18 | Completed | ||
| Regeneration in Cervical Degenerative Myelopathy - a Multi-centre, Double-blind, Randomised, Placebo Controlled Trial Assessing the Efficacy of Ibudilast as an Adjuvant Treatment to Decompressive Surgery for Degenerative Cervical Myelopathy[NCT04631471] | Phase 3 | 400 participants (Anticipated) | Interventional | 2021-12-22 | Recruiting | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
1 trial available for ibudilast and Allodynia
| Article | Year |
|---|---|
Glial Attenuation With Ibudilast in the Treatment of Medication Overuse Headache: A Double-Blind, Randomized, Placebo-Controlled Pilot Trial of Efficacy and Safety.
Topics: Adult; Area Under Curve; Double-Blind Method; Female; Headache Disorders, Secondary; Humans; Hyperal | 2015 |
5 other studies available for ibudilast and Allodynia
| Article | Year |
|---|---|
Ibudilast suppresses oxaliplatin-induced mechanical allodynia and neurodegeneration in rats.
Topics: Adenocarcinoma; Animals; Colonic Neoplasms; Hyperalgesia; Male; Mice; Oxaliplatin; Peripheral Nervou | 2021 |
Supradural inflammatory soup in awake and freely moving rats induces facial allodynia that is blocked by putative immune modulators.
Topics: Animals; Dura Mater; Encephalitis; Hyperalgesia; Inflammation Mediators; Macrophages; Male; Microgli | 2017 |
Supradural inflammatory soup in awake and freely moving rats induces facial allodynia that is blocked by putative immune modulators.
Topics: Animals; Dura Mater; Encephalitis; Hyperalgesia; Inflammation Mediators; Macrophages; Male; Microgli | 2017 |
Supradural inflammatory soup in awake and freely moving rats induces facial allodynia that is blocked by putative immune modulators.
Topics: Animals; Dura Mater; Encephalitis; Hyperalgesia; Inflammation Mediators; Macrophages; Male; Microgli | 2017 |
Supradural inflammatory soup in awake and freely moving rats induces facial allodynia that is blocked by putative immune modulators.
Topics: Animals; Dura Mater; Encephalitis; Hyperalgesia; Inflammation Mediators; Macrophages; Male; Microgli | 2017 |
Ibudilast reduces oxaliplatin-induced tactile allodynia and cognitive impairments in rats.
Topics: Analgesics; Animals; Antineoplastic Agents; Cognitive Dysfunction; Conditioning, Psychological; Fear | 2017 |
Ibudilast produces anti-allodynic effects at the persistent phase of peripheral or central neuropathic pain in rats: Different inhibitory mechanism on spinal microglia from minocycline and propentofylline.
Topics: Animals; Encephalomyelitis, Autoimmune, Experimental; Female; Humans; Hyperalgesia; Injections, Spin | 2018 |
Systemic administration of propentofylline, ibudilast, and (+)-naltrexone each reverses mechanical allodynia in a novel rat model of central neuropathic pain.
Topics: Animals; Disease Models, Animal; Hyperalgesia; Male; Naltrexone; Narcotic Antagonists; Neuralgia; Ne | 2014 |